Incyte Genomics Inc vs Abbvie Inc.
INCY vs ABBV — side-by-side comparison from reported financials. INCY leads 5, ABBV leads 3 of 8 comparable metrics.
Incyte Genomics Inc
INCY · Healthcare
$112.79+0.04%Mixed
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | INCY | ABBV |
|---|---|---|
| Price | $112.79 | $276.43 |
| Market cap | $22.9B | $488B |
| Revenue (TTM) | $5.82B | $64.4B |
| Revenue growth | +14.8% | +1.8% |
| Net margin | 27.7% | 9.8% |
| Free cash flow | $1.98B | $18.2B |
| Net cash (debt) | — | ($56.2B) |
| 1-year price return | +33.1% | +19.8% |
| P/E | 14.2 | 77.4 |
| P/E vs own history (cheap-side %) | 96% | 23% |
| Dividend yield | — | 2.45% |
| Return on equity | 30% | 96% |
| Altman Z-score | — | 2.33 |
| CV checks passed | 9 of 10 | 9 of 10 |
| Employees | 2,844 | 57,000 |
Full résumé-style profiles: INCY CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.